← Human Trials & Peer-Reviewed Studies
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
Plain-language guide to PMID 42419889 (2026): randomized and double-blind clinical study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 100 adults.
Key Facts
- PMID
- 42419889
- Journal
- BMJ open
- Year
- 2026
- Study type
- Clinical Study
- Authors
- Erlandson KM et al. (16 authors)
- DOI
- 10.1136/bmjopen-2026-120740
What This Study Did, in Plain Language
What Was Tested
This clinical study looks at Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).
Ethical approval for the TRIUMPH study was obtained from the Institutional Review Boards at participating sites.
All participants provide written informed consent prior to enrolment.
Who Took Part
The abstract describes 100 adults taking part.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.
TRIUMPH is a two-site, double-blind, randomised trial of 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.
The adults were allocated by chance, so the Tesamorelin group and the comparison group should start out alike.
Blinding on both sides kept the adults and researchers unaware of who received Tesamorelin.
A placebo (an inactive look-alike) gave the Tesamorelin group a baseline to be compared against.
More than one site took part, so the adults came from several places.
The researchers will determine short-term and sustained effects of tesamorelin plus exercise on clinical endpoints, including physical function, muscle content and quality, quality of life, and exercise adherence at Weeks 24 and 48.
The researchers also will elucidate effects of tesamorelin plus exercise on biological endpoints, including muscle fat and mitochondrial function at Week 24.
What Was Measured
Topics PubMed links to this paper include Growth Hormone-Releasing Hormone, HIV Infections, Randomized Controlled Trials as Topic, Quality of Life, Exercise Therapy and Frailty.
Author keywords: Aging and HIV & AIDS.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 100 adults.
The publication is from 2026 (BMJ open), a journal based in England.
More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Tesamorelin: GH pulse → liver IGF-1 → mTOR and PI3K-AKT (muscle).
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.